Urology Medical News about Prostate cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Slow zoledronic acid releasing testis prostheses in the treatment of prostate cancer patients with bone metastases
Medical Hypotheses, 05/01/09

Serefoglu EC et al. - Testicular prostheses have been shown to reduce the psychological impact resulting from loss or absence of a testicle in those patients. Zoledronic acid is the only bisphosphonate agent demonstrated to effectively reduce skeletal related events in patients with advanced prostate cancer metastatic to bone. Therefore, zoledronic acid releasing testicular prostheses can be used in the treatment of prostate cancer patients with bone metastases after bilateral orchiectomy. This technology has the potential to become the preferred clinical management tool for prostate cancer patients with bone metasthases after bilateral orchiectomy.

<< Previous
Seventeen Years Experience of Penile Fracture: Conservative vs....

Next >>
Prospectively Packaged Ilioinguinal Lymphadenectomy for Penile...